Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$185.68 USD

185.68
1,137,205

+0.90 (0.49%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Kaibalya Pravo Dey headshot

Coronavirus Vaccine Trial Begins, Biotech Competition Heats Up

While the overall vaccine development process has been impressively fast so far, it might take 12-18 months to fully validate a potential vaccine.

Kinjel Shah headshot

Coronavirus Drug Development Efforts Pick Up Amid Sell-Off

Several drug/biotech companies are working on making new antibodies, drugs and vaccines to prevent and treat COVID-19.

Ekta Bagri headshot

Biotech Sector in Focus as Coronavirus Spreads Panic

The outbreak of COVID-19 has brought the volatile biotech sector under the spotlight as both large and small companies rush to develop treatments and vaccines to combat this pandemic.

The Zacks Analyst Blog Highlights: Amazon, IBM, Biogen, Newmont and Berkshire Hathaway

The Zacks Analyst Blog Highlights: Amazon, IBM, Biogen, Newmont and Berkshire Hathaway

Mark Vickery headshot

Top Analyst Reports for Amazon, IBM & Biogen

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), International Business Machines Corporation (IBM) and Biogen Inc. (BIIB).

J&J Files MAA for Multiple Sclerosis Drug Ponesimod in Europe

Ponesimod's regulatory application in Europe is based on data from the head-to-head OPTIMUM phase III study comparing it to Sanofi's (SNY) MS drug, Aubagio

Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More

The biotech sector was in focus with new drug approvals, acquisitions and regular pipeline updates from quite a few companies.

AbbVie's Venclexta Combo Fails in Late-Stage Leukemia Study

AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with chemotherapy fails to achieve statistically significant improvement in overall survival in treatment-naive AML patients.

Zacks Market Edge Highlights: Tesla, Micron, Biogen, GameStop and Maxar Technologies

Zacks Market Edge Highlights: Tesla, Micron, Biogen, GameStop and Maxar Technologies

Tracey Ryniec headshot

Stocks the Pros Loved Heading into 2020

As stocks hit new all-time highs to finish 2019, the professional money managers were busy positioning their portfolios for 2020. What were they buying, and selling, heading into the new year?

Kevin Cook headshot

Bull of the Day: Guardant Health (GH)

Cancer diagnostics provider who delivered 181% revenue growth and 18,500 tests to patients and labs partners with Amgen

Sanghamitra Saha headshot

Wanna Be a Value Investor? Follow Buffett & Play 2 ETF Areas

Warren Buffett took positions in Biogen and Kroger. Investors who want to follow Buffett's picking of these two value stocks can also play these ETFs as well.

Alkermes' (ALKS) Earnings and Revenues Beat Estimates in Q4

Alkermes (ALKS) beats earnings and sales estimates in the fourth quarter of 2019.

Sweta Jaiswal, FRM headshot

Can Biotech ETFs Gain on Mixed Q4 Earnings Results?

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.

Western Union (WU) Q4 Earnings and Revenues Lag Estimates

Western Union (WU) delivered earnings and revenue surprises of -11.63% and -1.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

VAREX IMAGING (VREX) Q1 Earnings Miss Estimates

VAREX IMAGING (VREX) delivered earnings and revenue surprises of -25.00% and 4.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Diodes (DIOD) Q4 Earnings and Revenues Top Estimates

Diodes (DIOD) delivered earnings and revenue surprises of 3.17% and 0.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Lilly Reports Disappointing Data on Alzheimer's Candidate

Eli Lilly's (LLY) Alzheimer's disease drug, solanezumab, fails to meet primary endpoint in a phase II/III investigator-led study.

Roche Reports Disappointing Data on Alzheimer's Disease Drug

Roche's (RHHBY) Alzheimer's disease drug fails to meet primary endpoint in a phase II/III study.

Alkermes (ALKS) to Report Q4 Earnings: What's in Store?

We expect Alkermes (ALKS) to provide revenue updates on its proprietary marketed products and pipeline candidates when it releases fourth-quarter earnings on Feb 13.

Sheraz Mian headshot

Top Stock Research Reports for Alphabet, Roche & Amgen

Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Roche Holding (RHHBY) and Amgen (AMGN).

Biogen Soars on Patent Win for MS Drug Tecfidera Over Mylan

The U.S. Patent and Trademark Office imparts a ruling in favor of Biogen (BIIB) over generic drugmaker Mylan to protect the patent of its best-selling multiple sclerosis drug, Tecfidera.

Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod

Many biotech bigwigs came out with their fourth-quarter numbers in the past week.

Biogen (BIIB) Surpasses Q4 Earnings and Sales Estimates

Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The company expects decline in sales and earnings in 2020.

Biogen (BIIB) Q4 Earnings & Sales Beat Estimates

Biogen (BIIB) beats estimates for both earnings and sales in the fourth quarter.